Engichem Lifesciences announced on the 7th that it had achieved results in overseas sales, such as expanding exports of major products such as tuberculosis treatments and antitussives and securing new business partners, by participating in the Asian pharmaceutical and bio exhibition 'CPHI China 2025' held in Shanghai, China from June 24th to 26th.
'CPHI China' is a large-scale global industry exhibition with pharmaceutical and bio companies and experts from over 120 countries participating, and Enzychem Life Sciences set up a booth in the Korean Pavilion operated by the Ministry of Trade, Industry and Energy and KOTRA. During the event, it held practical supply negotiations with over 100 global companies.
Key achievements include discussions on expanding exports of the anti-tuberculosis drug 'Cycloserine' to Russia and resuming supplies to Kazakhstan. In particular, the expansion of exports to Russian company F is expected to lead to sales after the domestic audit scheduled for July. In addition, cooperation with pharmaceutical companies in countries such as Bulgaria and Turkey was also discussed.
In the case of the expectorant 'Erdostein', discussions were held with Bulgarian company S to expand into the Eastern European, Western European, and CIS markets, and discussions were held with Italian company E to establish a new distribution channel. In addition, discussions were held with a Pakistani pharmaceutical company to initiate a transaction for the muscle relaxant 'Eperisone', and with a Japanese company to discuss strategies for entering the Japanese market for the hyperparathyroidism treatment 'Evocalcet'.
In the new business sector, we reviewed the domestic distribution strategy for the obesity treatment drug 'Semaglutide' with a Chinese global company, and export negotiations for K-beauty cosmetic products were held in Bangladesh, Pakistan, Guatemala, and Russia.
An official from EngiChem Life Sciences said, “Through our participation in CPHI China, we were able to expand overseas exports of our existing flagship pharmaceuticals and secure many points of contact with new partners,” adding, “We plan to accelerate the increase in corporate value through new businesses such as obesity treatments and K-beauty products.”
- See more related articles
You must be logged in to post a comment.